Last updated on April 2017

Study of IW-1701 A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Type II Achalasia

Brief description of study

The objectives of this study are as follows: In patients with primary Type II Achalasia, following a single 5-mg dose of IW-1701, - To assess the safety and tolerability - To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) - To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast

Clinical Study Identifier: NCT02931565

Contact Investigators or Research Sites near you

Start Over

Cecile Guttermuth, PhD

Connecticut Clinical Research Foundation, Gastroenterology Institute
Bristol, CT United States
  Connect »

Clinical Research Coordinator

Northwestern University Feinberg School of Medicine, Division of Gastroenterology and Hepatology
Chicago, IL United States
  Connect »

Deborah M Geno, CCRP

Mayo Clinic
Rochester, MN United States
  Connect »

Terri Radake, RN, CRCC

Washington University in St. Louis - School of Medicine
Saint Louis, MO United States
  Connect »

Tina C Higginbotham, MPA

Vanderbilt University Medical Center
Nashville, TN United States
  Connect »